Literature DB >> 9790515

The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus.

J S Leinonen1, V Rantalaiho, P Laippala, O Wirta, A Pasternack, H Alho, O Jaakkola, S Ylä-Herttuala, T Koivula, T Lehtimäki.   

Abstract

Oxidation of low-density lipoprotein (LDL) may be an important factor in the development of diabetic macrovascular and renal complications. The level of autoantibodies against oxidized LDL (oxLDL-Ab) can be used as an index of LDL oxidation in vivo. The purpose of this study was to investigate the association between the level of oxLDL-Ab and the presence of coronary heart disease and renal dysfunction in patients with non-insulin-dependent diabetes mellitus (NIDDM). We determined the plasma levels of oxLDL-Ab in 46 NIDDM patients and 48 well matched nondiabetic control subjects. NIDDM patients had a moderately higher level of oxLDL-Ab than control subjects (0.083 +/- 0.051 vs. 0.062 +/- 0.045, p = 0.04). However, there was no difference in the level of oxLDL-Ab between subjects with and without coronary heart disease, and the level of oxLDL-Ab was not associated with indices of glomerular filtration rate or urinary albumin excretion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790515

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  5 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 3.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

4.  Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus.

Authors:  Wen-Nan Huang; Tim K Tso; Hui-Yu Huang
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

Review 5.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.